Matthew Perrone, Associated Press

Parents and anti-tobacco groups immediately criticized the decision, which follows years of advocacy efforts to keep menthol and other flavors that can appeal to teens off the market.

Government agencies have cracked down on some manufacturers of e-cigarettes, but thousands of unauthorized products continue to be sold in vape shops and convenience stores.

The nonbinding vote is a potential setback for psychedelic advocates hoping to move the banned drugs into the mainstream.

As artificial intelligence moves into medicine, perhaps no one has more to gain or lose than radiologists.

A one-month supply will cost about $20 and a three-month supply will cost around $50.

Drugmakers reformulated their pills and solutions with phenylephrine after a 2006 law required an older drug to be moved behind the counter.

Perrigo will start shipping the once-a-day Opill early next year, and there will be no age restrictions on sales.

If the agency follows the nonbinding recommendation, Perrigo’s drug Opill would become the first contraceptive pill to be moved from behind the pharmacy counter onto store shelves.

A Christian group is seeking to overturn the Food and Drug Administration’s more than 2-decade-old approval of an abortion medication, in a case that could threaten the most common form of abortion in the U.S.

U.S. health officials want to make COVID-19 vaccinations more like the annual flu shot.

The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease’s underlying biology.

The move follows years of pressure from medical experts and consumer advocates to make the devices cheaper and easier to get.

HRA Pharma’s application on Monday sets up a high-stakes decision for health regulators amid legal and political battles over women’s reproductive health.

The action is part of a sweeping effort by the Food and Drug Administration to bring scientific scrutiny to the multibillion-dollar vaping industry after years of regulatory delays.

Experts point to decades-old policies that have allowed a handful of companies to corner the infant formula market.